Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), executed a significant insider transaction on June 22, 2026, selling 18,197 shares of the company’s Class A Common Stock. The total value of the sale reached $619,216. The shares were disposed of at an average weighted price of $34.0285, with individual transactions occurring within a specific price range of $33.65 to $34.57. This activity took place while the stock was trading at $32.96, a level that assigns the telehealth company a market capitalization of $7.65 billion. According to InvestingPro analysis, HIMS appears overvalued at current levels, placing it among companies on the Most Overvalued list. The platform notes that stock price movements are quite volatile, with shares trading between $13.74 and $70.43 over the past year.
The sale followed the exercise of 6,376 stock options, which converted into Class A Common Stock at an exercise price of $5.01 per share, totaling $31,943. Both the option exercise and the subsequent sale were executed under a Rule 10b5-1 trading plan, which was adopted by Mr. Okupe on May 21, 2025. Following these transactions, Mr. Okupe directly holds 284,321 shares of Class A Common Stock. For investors seeking deeper insights into HIMS’s executive compensation and insider trading patterns, InvestingPro offers 10 additional ProTips and comprehensive analysis, including detailed Pro Research Reports available for over 1,400 US equities. Additionally, 7,853 shares are held indirectly through the Oluyemi Okupe Separate Property Trust dtd 9-1-2021. Mr. Okupe also holds 109,524 stock options. The options exercised on June 22, 2026, were part of a grant where 25% vested on the twelve-month anniversary of the January 24, 2022, vesting commencement date, with the remainder vesting in 36 successive equal monthly installments thereafter, subject to continuous service.
In other recent news, Hims & Hers Health has seen several notable developments. Barclays has raised its price target for the company to $39, up from $29, while maintaining an Overweight rating. This adjustment comes after improvements linked to the company’s partnership with Novo Nordisk, which resulted in increased website traffic in recent months. Meanwhile, Leerink has reiterated a Market Perform rating with a $25 price target as the company prepares for a regulatory meeting on compounded peptides. The Pharmacy Compounding Advisory Committee is set to discuss the inclusion of peptides on a list that would allow drug compounders to produce them.
In corporate governance, Hims & Hers Health held its annual meeting where all nine director nominees were elected to serve until 2027. The company also announced the appointment of Dr. Anant Vinjamoori as Chief Medical Officer for the Hims brand. Dr. Vinjamoori will oversee clinical guidance across various health categories, including sexual health and peptide therapy. These developments highlight the company’s ongoing strategic initiatives and management changes.